BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/14/2023 7:03:17 AM | Browse: 177 | Download: 734
 |
Received |
|
2022-10-24 08:23 |
|
Peer-Review Started |
|
2022-10-04 04:04 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-12-19 07:27 |
|
Revised |
|
2023-01-08 10:24 |
|
Second Decision |
|
2023-01-20 03:13 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-01-20 05:54 |
|
Articles in Press |
|
2023-01-20 05:54 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-02-02 16:06 |
|
Publish the Manuscript Online |
|
2023-02-14 07:03 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Respiratory System |
| Manuscript Type |
Case Report |
| Article Title |
Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mei-Hong Liu, Yan-Xia Li and Zhuo Liu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| the Foundation of Science and Technology Bureau of Dalian |
2021JJ13SN70 |
|
| Corresponding Author |
Zhuo Liu, PhD, Doctor, Doctor, Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital of Dalian Medical University, No. 222 Zhongshan Road, Dalian 116011, Liaoning Province, China. liuzhuo@firstosp-dmu.com |
| Key Words |
Combined small cell lung cancer; Envafolimab; Carboplatin; Etoposide; Prognosis; Case report |
| Core Tip |
Combined small cell lung cancer (C-SCLC) is a special subtype of small cell lung cancer, which is relatively rare, aggressive, prone to early metastasis, and has a poor prognosis. With the development and progress of immunotherapy, several clinical studies have shown that programmed death ligand-1 combined with chemotherapy can effectively prolong the progression-free survival and median overall survival of patients with extensive stage small cell lung cancer, but its efficacy in C-SCLC is not exact. In this paper, we report a patient with extensive stage C-SCLC who was treated with envafolimab combined with carboplatin and etoposide with preliminary anti-tumor activity, safety and tolerability. |
| Publish Date |
2023-02-14 07:03 |
| Citation |
Liu MH, Li YX, Liu Z. Envafolimab combined with chemotherapy in the treatment of combined small cell lung cancer: A case report. World J Clin Cases 2023; 11(5): 1115-1121 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i5/1115.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i5.1115 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
